Palatin Technologies, Inc. (0KF3) Earnings Call Transcript & Summary
May 14, 2025
Earnings Call Speaker Segments
Operator
operatorHello, everyone. Thank you for joining us for Palatin's conference call on operating results for the third quarter of fiscal year 2025. Right now, every participant is in listen-only mode. After the formal presentation, there will be a question and answer session. Please note that this conference call is being recorded. Before we get into our remarks, I want to point out that anything Palatin states which is not a historical fact could constitute a forward-looking statement. Such statements rest on assumptions that might or might not turn out to be accurate, and actual results could differ materially from what is anticipated because of the various risks and uncertainties covered in the company's latest filings with the Securities and Exchange Commission. As you evaluate these forward-looking statements regarding Palatin's prospects, we ask that you carefully take such risks and uncertainties into account. I'll now hand the call over to our host, Dr. Carl Spana, Palatin's President and Chief Executive Officer.
Carl Spana
executiveThanks. Morning, everyone, and thanks for joining Palatin's call covering the third quarter of fiscal year 2025. Dr. Carl Spana here — I serve as CEO and president of Palatin. Joining me today is Steve Wills, who holds the roles of Chief Financial Officer and Chief Operating Officer at Palatin. At this point I'll hand things over to Steve, who will walk through the financial update.
Stephen Wills
executiveThank you, Carl. Good morning. Good afternoon, everyone. Turning to the nonprogram corporate update: on May 7, 2025, Palatin was notified by NYSE regulation that trading of the company's common stock on the NYSE American Stock Exchange had been suspended, and that it had decided to begin proceedings to delist Palatin's common stock. That determination rested on a finding that the company is no longer suitable for listing under Section 1003 F5 of the NYSE American Company Guide, owing to the low selling price of the company's common stock. Trading of the company's common stock on the NYSE American was suspended on May 7, 2025, and began trading on the OTC Pink market on May 8, 2025. Palatin exercised our right to review of NYSE regulations' determination to delist Palatin's common stock. We are disappointed and do not agree with the NYSE's decision and are assessing all available options. Moving over to our fiscal third quarter ended March 31, 2025 financial results. Regarding revenue, pursuant to the completion of the sale of Vyleesi's worldwide rights for female sexual dysfunction to Cosette Pharmaceuticals for up to $171 million in December 2023, Palatin did not record any product sales to pharmacy distributors for the quarter ended March 31, 2025 and March 31, 2024.
Stephen Wills
executiveNow on operating expenses: for the quarter ended March 31, 2025, total operating expenses came in at $4.8 million, net of a $0.4 million gain on a purchase commitment. That compares with $9.2 million in the same quarter last year. The drop was primarily driven by lower spending on our MCR programs during the quarter ended March 31, 2025. Turning to cash flows: Palatin's net cash used in operations for the quarter ended March 31, 2025, was $5.4 million, versus net cash used in operations of $8.6 million for the same period in 2024. That reduction in net cash used in operations stems mainly from the smaller net loss during the period, and secondarily from working capital changes. On net loss: Palatin's net loss for the quarter ended March 31, 2025, was $4.8 million, compared with a net loss of $8.4 million for the same period in 2024. As I mentioned above, the narrowing of the net loss for the quarter ended March 31, 2025, over the quarter ended March 31, 2024, was driven primarily by the decrease in operating expenses for the quarter ended March 31, 2025. Finally, on cash position: as of March 31, 2025, Palatin's cash and cash equivalents stood at $2.5 million, compared with cash and cash equivalents of $9.5 million at June 30, 2024.
Stephen Wills
executiveAs of March 31, 2025, we held $2.5 million in cash and cash equivalents, and that figure excludes roughly $3.5 million in net proceeds that came in during April and May 2025 from Palatin's ATM facility and the recent equity offering. We're actively working with several possible sources of funding, including business development efforts, to address future operating cash needs. With that, I'll hand the call back to Carl.
Carl Spana
executiveThanks, Steve. Moving on to the operating update for the quarter. Here's where things stand with the melanocortin-4 receptor obesity programs. In our Phase 2 study, BMT-801, which is assessing the safety and efficacy of co administering the melanocortin-4 receptor agonist Bremelanotide together with Tirzepatide, a GLP-1/GIP dual agonist, in patients with generalized obesity, we announced positive top line data. The research questions were successfully answered by the study: does co administration lead to greater weight loss, and can a melanocortin-4 receptor agonist be used to treat weight loss maintenance by blunting the weight regain that is seen after in treatment therapy ends? The primary efficacy endpoint was weight loss for the combined treatment versus a placebo control at the conclusion of eight weeks of treatment. Weight reduction among patients on the combined therapy was 4.4%, versus 1.6% in the placebo arm. The P value here was highly significant. Importantly, 19% of patients on the combined treatment achieved a weight reduction of greater than 7%, compared to 0% for patients on placebo and the Tirzepatide alone arms. As for a weight loss maintenance effect, a low dose of Bremelanotide prevented the rapid weight regain that followed Tirzepatide treatment. So a very positive study for us.
Carl Spana
executiveLooking ahead, our portfolio for obesity and weight loss management covers a novel long-acting melanocortin-4 selective peptide agonist as well as the orally active melanocortin-4 receptor selective small molecule agonist PL7737. In the quarter, the FDA informed us that PL7737 received orphan drug designation for the treatment of patients with obesity caused by leptin receptor deficiency. Subject to financing, PL7737 remains on schedule for an initial new drug application submission in Phase 1 single ascending dose and multiple ascending dose studies during the first quarter of 2026. Our novel next generation selective melanocortin-4 receptor compounds show lower activity at the melanocortin-1 receptor, which lowers the potential for skin darkening. This absence of MCR-1 activity with once weekly or oral dosing represents meaningful improvements compared with the melanocortin treatments currently approved by the FDA. Additional information about our clinical trial is available at clinicaltrials.gov and on our website. In the quarter, we also announced positive top line data from a Phase 2 study of our oral PL-8177, a selective melanocortin-1 receptor agonist being evaluated for ulcerative colitis. The trial compared PL-8177 with placebo over eight weeks in patients with moderate ulcerative colitis. Clinical remission was reached by 33% of patients treated with PL-8177 compared with 0% on placebo.
Carl Spana
executiveFor 78% of patients on PL-8177, we saw a clinical response — versus 33% on placebo, which again is highly significant. Symptomatic remission occurred in 56% percent of those treated with PL-8177, compared with 33% for placebo. These exciting results have led to a substantial uptick in business development conversations with prospective partners, consistent with our present strategy of out-licensing this program. In the quarter, we also shared further data from the PL-9643 MELLODY-1 Phase 3 trial in patients with dry eye disease. A responder analysis contrasting placebo with PL9643 showed that on 6 of the 13 symptom endpoints, a significantly greater proportion of patients experienced complete symptom clearing — that is, they were cured. That too was highly significant. No FDA approved therapy for dry eye disease has reached this degree of symptom clearing. Clearing emerged as early as two weeks and kept improving across the 12 weeks of the study. We are actively working with potential corporate partners on this program, one of our earlier ocular programs, and we expect one or more transactions to close in the second half of calendar '25. Before I move on to take questions, I'd like to comment on our strategy.
Carl Spana
executiveOur research and development work is concentrated on the obesity assets targeting the melanocortin-4 receptor. In our view, pharmacological obesity treatment sits at the beginning of a multiyear innovation cycle and will be worth more than $100 billion annually. The melanocortin system is critically important in regulating stored energy and food intake, and we strongly believe the melanocortin-4 receptor agonist will play an important part in the future of obesity treatment and weight loss management. Thank you for participating, and we'll now open the line for questions.
Operator
operatorScott Henry from Alliance Global Partners has a question for us. Scott, your line is open now, so please proceed.
Scott Henry
analystI have a couple of questions regarding the obesity program. To start, I understand that this study used a low dose of Bremelanotide, or BMT. What I'd like to know is whether you think a higher dose would lead to greater weight loss, bringing it into the ranges seen with Wegovy or Zepbound?
Carl Spana
executiveYes, there's actually a publication we have on that. In a progress study, we examined higher doses of Bremelanotide, and the goal there was optimization — since it's a short-acting compound, patients took multiple doses each day, which kept them in the optimal dose range whenever they had access to food. The weight loss seen there is truly comparable to what you'd observe with the single agent Wegovy. Tirzepatide works through multiple mechanisms, and it's somewhat better than Wegovy. However, when it comes to these single mechanism drugs such as Wegovy, a good MCR4 agonist like Bremelanotide or the ones we're developing will deliver highly competitive weight loss.
Scott Henry
analystSo with the GLPs, regaining weight after stopping is a fairly common problem. Do you think this concept of maintaining weight might emerge down the road, and could it even make its way into the label at some point? Might that become a bigger focus in the next generations?
Carl Spana
executiveSure. The novel compounds in development will be assessed for weight loss maintenance. Studies are underway at this moment evaluating that with the GLP1. Even so, you'll require additional mechanisms to truly tackle it over the long term. At present, we have no evidence that once patients have shed pounds, they can successfully stop treatment and keep that weight off. As things stand, the approach is that they will need long-term weight loss maintenance — you know, how dosing plays out, which agents get used, you know, that will be figured out through clinical trials. Melanocortin-4 agonists are genuinely well suited to that. It's likely dysfunction in the hypothalamic MCR leptin pathways that is in fact driving that weight regain, and this genuinely starts to target it head-on.
Scott Henry
analystAnd for the last question, regarding the next generation of MC4Rs, could you describe the advantages that are going to set them apart from the first generation? Pigmentation was a problem. I’m not sure whether that will be one of the things that turns out differently. But could you just share what you expect from that next generation?
Carl Spana
executiveOkay, thank you. Bremelanotide and Setmelanotide — the other approved one — are what I'd call first-generation compounds. They're good and they work well, but dosing is short term, meaning at least one dose daily, sometimes more. As you mentioned, they do cause pigmentation. In something like a general market, they aren't ideal treatments or as competitive as what's currently available. So our aim here is essentially to remove that MCR-1 activity, so skin darkening doesn't occur. I believe we've managed that pretty effectively. Beyond that, with a peptide — not something orally active — we definitely want once-weekly dosing, which is quite patient friendly, or, with 7737, a small molecule, we want a once-a-day oral with a really favorable extended half-life, letting us truly reach steady state. That's genuinely the objective with these programs. On the melanocortin side, compared with what exists today, when you're working with short-acting compounds, maintaining steady state is, as you know, extremely difficult. With obesity, reaching that steady state matters a great deal, and we can get there with either the long-acting peptide or the oral small molecule we're advancing.
Carl Spana
executiveThey genuinely represent upgrades compared with what's available on the market right now.
Operator
operatorThanks. That brings today’s question-and-answer session to an end. At this point, I’d like to hand things back to management for their closing remarks.
Carl Spana
executiveSteve and I want to thank all of you for joining our call for the third quarter of fiscal year 2025. We're eager to keep you informed about how things are going. From an operating perspective, I'd say this was a phenomenal quarter for us. We did run into a bit of difficulty with the MISC, though I believe that will be transitory. We're going to work to address it as quickly as we can. So thank you, and please have a great day.
Operator
operatorThanks. That brings us to the end of today's conference call. At this point you can disconnect, and we hope you have a wonderful day. We appreciate your participation.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Palatin Technologies, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Palatin Technologies, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Palatin Technologies, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.